key: cord-0716126-9z7u1dln
authors: Luczkowiak, Joanna; Labiod, Nuria; Rivas, Gonzalo; Rolo, Marta; Lasala, Fátima; Lora-Tamayo, Jaime; Mancheno-Losa, Mikel; Rial-Crestelo, David; rez-Rivilla, Alfredo Pé; Folgueira, María Dolores; Delgado, Rafael
title: Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naïve and COVID-19 convalescent individuals
date: 2021-12-28
journal: J Infect Dis
DOI: 10.1093/infdis/jiab634
sha: 8eb25d63817d5bda082b76c54eddfdc662f7d7f4
doc_id: 716126
cord_uid: 9z7u1dln

We have investigated the evolution of the neutralizing response against SARS-CoV-2 variants at 8 months after Pfizer-BNT162b2 vaccination in COVID-19 naïve (n=21) and COVID-19 convalescent (n=21) individuals. Neutralizing levels declined for all variants (range 2-3.7-fold). Eight months after vaccination a significant proportion (4/21) of naïve individuals lacked detectable neutralizing activity against the highly transmissible SARS-CoV-2 delta variant. In the “convalescent” group the impressive high initial humoral response resulted in detectable neutralizing antibody levels against all variants throughout this period.

M a n u s c r i p t 6 Background:

Vaccination against SARS-CoV-2 is highly protective against severe forms of COVID-19 and its deployment has enormously helped to control the spread of the pandemic(1, 2); however, the selection of SARS-CoV-2 variants associated with an increased transmissibility can also determine immune escape to neutralizing antibodies induced by natural infection or vaccination thus jeopardizing pandemic control. Furthermore, waning of vaccine efficacy has been reported, and breakthrough infections in vaccinated individuals have been correlated to low levels of neutralizing antibodies (3) . In this study we have aimed to investigate the evolution of the neutralizing antibody response against SARS-CoV-2 variants of concern (VoC) at 8 In our study we have detected a significant reduction of RBD binding antibodies from month 2, at the presumably higher level of response, to month 8 post BNT162b2 

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Breakthrough Infections in Vaccinated Health Care Workers

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV

Variants in Naïve and COVID-19-Convalescent Individuals

Correlates of protection induced by vaccination

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

Adaptive immunity to SARS-CoV-2 and COVID-19

Waning Immunity after the BNT162b2 Vaccine in Israel

Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study

Vaccine Effectiveness by Product and Timing in New York State

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

A c c e p t e d M a n u s c r i p t 14